AZURITY Wins FDA Approval for DANZITEN™ Tablets with No Mealtime Restrictions
Details : Danziten (nilotinib), an oral BCR-ABL kinase inhibitor, it is indicated for treating adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia.
Brand Name : Danziten
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 14, 2024
Xspray Pharma’s XS003 Study Shows Lower Dose Bioavailability vs. Tasigna
Details : XS003 (nilotinib), an oral BCR-ABL kinase inhibitor, is designed to overcome crystalline formulation limitations. In the study, XS003 shows bioavailability matching Tasigna at a 50% reduced dose.
Brand Name : XS003
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 09, 2024
Aurobindo Pharma Arm Signs Pact with Medicines Patent Pool to Develop Anti-Cancer Drug
Details : The agreement aims to to develop and market an anti-cancer drug, Tasigna (nilotinib), a transduction inhibitor, used for treatment of chronic myeloid leukemia.
Brand Name : Tasigna-Generic
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 23, 2023
KeifeRx Completes $6 Million Series A Financing and Enhances Board of Directors
Details : Proceeds from the financing will advance pipeline of optimized, low dose, orally delivered tyrosine kinase inhibitors including Nilotinib BE for the treatment of multiple neurodegenerative diseases.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 08, 2021
LOOKING FOR A SUPPLIER?
Reset All
